457 related articles for article (PubMed ID: 8647793)
1. OCD: where the serotonin selectivity story begins.
Pigott TA
J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
[TBL] [Abstract][Full Text] [Related]
2. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
5. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
6. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses.
Blier P; de Montigny C
Biol Psychiatry; 1998 Sep; 44(5):313-23. PubMed ID: 9755353
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
Flament MF; Bisserbe JC
J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
Okamoto Y
Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for obsessive-compulsive disorder.
Hollander E; Kaplan A; Allen A; Cartwright C
Psychiatr Clin North Am; 2000 Sep; 23(3):643-56. PubMed ID: 10986733
[TBL] [Abstract][Full Text] [Related]
10. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy of obsessive compulsive disorder.
DeVeaugh-Geiss J
Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
[TBL] [Abstract][Full Text] [Related]
13. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
14. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.
Shanahan NA; Velez LP; Masten VL; Dulawa SC
Biol Psychiatry; 2011 Dec; 70(11):1039-48. PubMed ID: 21920503
[TBL] [Abstract][Full Text] [Related]
15. Issues in the pharmacological treatment of obsessive-compulsive disorder.
Math SB; Janardhan Reddy YC
Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
[TBL] [Abstract][Full Text] [Related]
16. The pathogenesis and treatment of obsessive-compulsive disorder.
Dolberg OT; Iancu I; Sasson Y; Zohar J
Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of obsessive compulsive disorder.
Goodman WK; McDougle CJ; Price LH
J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
[TBL] [Abstract][Full Text] [Related]
18. A review of pharmacologic treatments for obsessive-compulsive disorder.
Kaplan A; Hollander E
Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
Goodman WK; Ward H; Kablinger A; Murphy T
J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of serotonergic drugs: focus on OCD.
Marazziti D; Avella MT; Basile L; Mucci F; Dell'Osso L
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):261-273. PubMed ID: 30793987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
